Cytek Biosciences (CTKB) Capital Expenditures (2020 - 2026)

Cytek Biosciences has reported Capital Expenditures for 7 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 54.06% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $588000.0 (down 20.33% YoY), and the FY2025 full-year result was $129000.0, down 27.12% from the prior year.
• Capital Expenditures for Q1 2026 stood at $1.3 million, up from $44000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $4.6 million in Q4 2023, with the low at -$2.3 million in Q3 2025.
• Historically, Capital Expenditures has averaged $461705.9 across 5 years, with a median of $288000.0 in 2024.
• Annual changes were most pronounced in 2022 — Capital Expenditures surged 872.57% — and 2024, when it sank 2404.55%.
• Cytek Biosciences' Capital Expenditures stood at $1.4 million in 2022, then surged by 236.69% to $4.6 million in 2023, then slumped by 98.29% to $78000.0 in 2024, then sank by 43.59% to $44000.0 in 2025, then soared by 2872.73% to $1.3 million in 2026.
• The last three Capital Expenditures figures came in at $1.3 million (Q1 2026), $44000.0 (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.